Scholar Rock Holding Co. (NASDAQ:SRRK) Forecasted to Post Q2 2022 Earnings of ($1.17) Per Share

Scholar Rock Holding Co. (NASDAQ:SRRKGet Rating) – Investment analysts at Wedbush lifted their Q2 2022 earnings estimates for Scholar Rock in a research report issued to clients and investors on Tuesday, May 17th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.17) for the quarter, up from their prior estimate of ($1.23). Wedbush currently has a “NA” rating and a $33.00 price target on the stock. Wedbush also issued estimates for Scholar Rock’s Q3 2022 earnings at ($0.97) EPS, Q4 2022 earnings at ($0.57) EPS, FY2022 earnings at ($2.80) EPS, Q1 2023 earnings at ($0.61) EPS, Q2 2023 earnings at ($0.67) EPS, Q3 2023 earnings at ($0.60) EPS, Q4 2023 earnings at ($0.54) EPS, FY2023 earnings at ($2.42) EPS, FY2024 earnings at ($1.77) EPS and FY2025 earnings at ($0.39) EPS.

Scholar Rock (NASDAQ:SRRKGet Rating) last issued its earnings results on Monday, March 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.08. The business had revenue of $4.05 million for the quarter, compared to analysts’ expectations of $4.33 million. Scholar Rock had a negative return on equity of 64.57% and a negative net margin of 700.46%. During the same period in the previous year, the firm posted ($2.81) EPS.

A number of other equities analysts have also recently issued reports on SRRK. Piper Sandler decreased their target price on Scholar Rock from $56.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday. Zacks Investment Research upgraded Scholar Rock from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a report on Wednesday, May 11th. HC Wainwright initiated coverage on Scholar Rock in a report on Wednesday, March 23rd. They set a “buy” rating and a $24.00 price target on the stock. Finally, BMO Capital Markets lowered their price target on Scholar Rock from $74.00 to $55.00 in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $29.08.

Shares of NASDAQ SRRK opened at $5.28 on Thursday. The company has a quick ratio of 4.13, a current ratio of 4.13 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $186.39 million, a price-to-earnings ratio of -1.74 and a beta of 0.60. The stock’s fifty day simple moving average is $10.20 and its 200 day simple moving average is $18.39. Scholar Rock has a 52-week low of $5.02 and a 52-week high of $44.95.

Several hedge funds have recently modified their holdings of SRRK. BlackRock Inc. grew its stake in Scholar Rock by 4.1% in the fourth quarter. BlackRock Inc. now owns 2,288,026 shares of the company’s stock valued at $56,835,000 after purchasing an additional 89,921 shares in the last quarter. State Street Corp grew its stake in Scholar Rock by 20.5% in the first quarter. State Street Corp now owns 1,502,501 shares of the company’s stock valued at $19,367,000 after purchasing an additional 255,624 shares in the last quarter. Vanguard Group Inc. grew its stake in Scholar Rock by 2.7% in the first quarter. Vanguard Group Inc. now owns 1,490,795 shares of the company’s stock valued at $19,217,000 after purchasing an additional 38,917 shares in the last quarter. Victory Capital Management Inc. grew its stake in Scholar Rock by 14.5% in the first quarter. Victory Capital Management Inc. now owns 1,458,128 shares of the company’s stock valued at $18,795,000 after purchasing an additional 184,935 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Scholar Rock by 124.9% in the third quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company’s stock valued at $42,150,000 after purchasing an additional 708,831 shares in the last quarter. Institutional investors and hedge funds own 84.22% of the company’s stock.

Scholar Rock Company Profile (Get Rating)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Read More

Earnings History and Estimates for Scholar Rock (NASDAQ:SRRK)

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.